(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more (MM) Charts. Click Here for more (MM) Charts.](/p.php?pid=staticchart&s=N%5EIDIX&p=8&t=15)
Pamela Thomas-Graham, Chairman of CNBC, Appointed to Board of
Directors of Idenix Pharmaceuticals
CAMBRIDGE, Mass., May 18 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals,
Inc. (NASDAQ:IDIX), a biopharmaceutical company engaged in the discovery,
development and commercialization of drugs for the treatment of human viral and
other infectious diseases, today announced Pamela Thomas-Graham, Chairman of
CNBC, has been elected to the company's Board of Directors. Ms. Thomas- Graham
will replace a seat vacated by Ansbert Gadicke, who has resigned his board
position. Both of these changes are effective immediately.
"As Idenix is moving from a research and clinical organization to that of a
company with commercial products, we believe Pamela's leadership experience and
strategic insights will contribute substantially to the Idenix Board and its
committees," said Jean-Pierre Sommadossi, chairman and chief executive officer
of Idenix. "We are pleased to have Pamela join us."
Sommadossi continued, "I want to take this opportunity to thank Ansbert for his
contributions to Idenix. His support since the founding of Idenix in 1998 has
been critical to our success to date."
Ms. Thomas-Graham is currently the Chairman of CNBC, the global business leader
in television business news. Prior to being promoted to Chairman in February
2005, Ms. Thomas-Graham served as President and Chief Executive Officer of
CNBC, from 2001 to 2005 and as an Executive Vice President of NBC, and
President and Chief Executive Officer of CNBC.com from 1999 to 2001. Ms.
Thomas-Graham joined NBC in 1999 after 10 years at McKinsey & Company, where
she was elected partner in 1995. In addition to her work at CNBC, Ms. Thomas-
Graham is also the author of the Ivy League mystery series published by Simon &
Schuster, which includes the bestselling novels entitled Blue Blood, A Darker
Shade of Crimson and Orange Crushed. Ms. Thomas-Graham holds a J.D. from
Harvard Law School, where she served as an editor of the Harvard Law Review,
and an M.B.A. from the Harvard Business School. Ms. Thomas-Graham is a Phi
Beta Kappa graduate of Harvard College.
About Idenix
Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) is a biopharmaceutical company
engaged in the discovery, development and commercialization of drugs for the
treatment of human viral and other infectious diseases. Idenix's current focus
is on the treatment of infections caused by hepatitis B virus, hepatitis C
virus and human immunodeficiency virus (HIV). Idenix's headquarters are located
in Cambridge, Massachusetts. The company also has drug discovery and
development operations in Montpellier, France and drug discovery operations in
Cagliari, Italy. For further information about Idenix, please refer to
http://www.idenix.com/.
Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of
The Private Securities Litigation Reform Act of 1995. Statements in this press
release other than those that are historical in nature are "forward-looking
statements." Forward looking statements, which include statements with respect
to the potential therapeutic benefits and successful development of the
company's product candidates and the company's drug discovery and research,
regulatory approval processes and commercialization activities, are subject to
numerous factors, risks and uncertainties that may cause actual events or
results to differ materially from the company's current expectations. These
risks and uncertainties relate to the results of clinical trials and other
studies with respect to the product candidates that the company has under
development; the timing and success of submission, acceptance and approval of
regulatory filings; the company's dependence on its collaboration with Novartis
Pharma AG; the company's ability to obtain additional funding required to
conduct its research, development and commercialization activities; the ability
of the company to attract and retain qualified personnel and the company's
ability to obtain, maintain and enforce patent and other intellectual property
protection for its product candidates and its discoveries. These and other
risks are described in greater detail under the caption "Factors That May
Affect Future Results" in the company's quarterly report on Form 10-Q for the
quarter ended March 31, 2005 and filed with the Securities and Exchange
Commission and other filings that the company makes with the Securities and
Exchange Commission.
All forward-looking statements reflect the company's expectations only as of
the date of this release and should not be relied upon as reflecting the
company's views, expectations or beliefs at any date subsequent to the date of
this release. Idenix anticipates that subsequent events and developments may
cause these views, expectations and beliefs to change. However, while Idenix
may elect to update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so.
Contact:
Idenix Pharmaceuticals, Inc.
Media: Teri Dahlman (617) 995-9905
Investors: Amy Sullivan (617) 995-9838
DATASOURCE: Idenix Pharmaceuticals, Inc.
CONTACT: Media: Teri Dahlman, +1-617-995-9905, or Investors: Amy
Sullivan, +1-617-995-9838, both of Idenix Pharmaceuticals, Inc.
Web site: http://www.idenix.com/